The US Food and Drug Administration has issued an update to its over-the-counter sunscreen monograph that adds a new ultraviolet filter to the list of actives permitted under the GRASE pathway, according to legal-regulatory trade publication COSlaw.eu, which flagged the Federal Register filing.

What the monograph governs

The sunscreen monograph sits within 21 CFR Part 352 and sets the conditions under which sunscreen drug products can be sold in the United States without individual new drug applications. It defines permitted active ingredients, concentration ranges, UV protection testing (SPF and broad spectrum), the Drug Facts label format, and dosage form restrictions.

Any active added to the monograph must clear FDA's Generally Recognized As Safe and Effective determination, a standard that requires data on safety, photostability, percutaneous absorption, and systemic exposure. The newly recognized ingredient therefore represents a documented shift from FDA's prior position—either GRASE-eligible status, or relief from a previous "insufficient data" finding for an older chemical filter.

What changes for formulators

US brands can now incorporate the added filter into formulations that meet the monograph's conditions, including finished-product SPF, broad-spectrum, and water-resistance claims. Manufacturers marketing products with the new active must still verify that:

• The concentration falls within the monograph range
• Combination restrictions with other actives are observed
• The finished product passes FDA-recognized test methods
• Drug Facts labeling reflects current monograph language

Formulators still relying on older permitted-only lists should audit their ingredient decks against the revised monograph text. Discontinued actives, renamed ingredients, or changed concentration caps can quietly push a finished product out of monograph compliance even when the formula looks unchanged.

Compliance workload

Regulatory affairs teams typically move through five steps within days of a monograph amendment:

• Pull the Federal Register notice and identify the effective date and any grace period for existing inventory
• Update product dossiers, formulation records, and stability protocols
• Revise Drug Facts labels and outer cartons
• Notify contract manufacturers and component suppliers of the new permitted combination
• Confirm testing partners use FDA-accepted in vivo SPF and in vitro broad-spectrum methods

Procurement should also be flagged. A new GRASE-allowed filter reshapes the US supplier landscape; distributors that previously routed customers toward mineral-only or older chemical filters will need updated chain-of-custody documentation, certificates of analysis, and impurity profiles for the active raw material.

What to watch next

The full Federal Register notice will resolve several open questions: the precise effective date, any transition period for products already on shelf, concentration caps, formulation restrictions, and whether the new filter carries any sunscreen-specific labeling claims. Industry comments on monograph amendments are typically due 30 to 60 days after publication, though some revisions carry longer transition windows under the OTC monograph reform framework established by the CARES Act.

Brands operating in both the US and the EU should track the European Commission's separate positive list under the Cosmetics Regulation. A US GRASE determination does not automatically confer EU compliance, and several filters widely used in Europe have remained in US pending status for years. The next data point to watch is the Federal Register text itself—particularly the effective date and any phase-out language for the previously non-GRASE ingredient list.